이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Castle Biosciences 관리

관리 기준 확인 4/4

Castle Biosciences' CEO는 Derek Maetzold, Sep2007 에 임명되었습니다 의 임기는 16.75 년입니다. 총 연간 보상은 $ 1.61M, 42.7% 로 구성됩니다. 42.7% 급여 및 57.3% 보너스(회사 주식 및 옵션 포함). 는 $ 8.75M 가치에 해당하는 회사 주식의 1.43% 직접 소유합니다. 8.75M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 3.6 년입니다.

주요 정보

Derek Maetzold

최고 경영자

US$1.6m

총 보상

CEO 급여 비율	42.7%
CEO 임기	16.8yrs
CEO 소유권	1.4%
경영진 평균 재임 기간	3.9yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

CEO 보상 분석

Derek Maetzold 의 보수는 Castle Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$2m	US$686k	-US$57m
Sep 30 2023	n/a	n/a	-US$76m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$72m
Dec 31 2022	US$8m	US$660k	-US$67m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$7m	US$625k	-US$31m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$5m	US$550k	-US$10m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	US$7m
Mar 31 2020	n/a	n/a	US$6m
Dec 31 2019	US$4m	US$770k	US$3m
Sep 30 2019	n/a	n/a	US$4m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$791k	US$410k	-US$10m

보상 대 시장: Derek 의 총 보상 ($USD 1.61M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.43M ).

보상과 수익: Derek 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Derek Maetzold (62 yo)

16.8yrs

테뉴어

US$1,605,984

보상

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...

리더십 팀

이름	위치	테뉴어	보상	소유권
Derek Maetzold	Founder	16.8yrs	US$1.61m	1.43% $ 8.6m
Frank Stokes	CFO & Treasurer	6.6yrs	US$880.25k	0.15% $ 888.7k
Kristen Oelschlager	Chief Operating Officer	3.9yrs	US$828.48k	0.55% $ 3.3m
Tobin Juvenal	Chief Commercial Officer	3.9yrs	US$829.10k	0.18% $ 1.1m
Camilla Zuckero	Vice President of Investor Relations & Corporate Affairs	no data	데이터 없음	데이터 없음
Alice Izzo	Senior Vice President of Marketing	6.3yrs	데이터 없음	데이터 없음
Kevin Doman	Vice President of Sales	2.1yrs	데이터 없음	데이터 없음
Keli Greenberg	VP of Human Resources & Executive Director of Human Resources	4yrs	데이터 없음	데이터 없음
Robert Cook	Senior Vice President of Research & Development	3.8yrs	데이터 없음	데이터 없음
Matthew Goldberg	Senior Vice President of Medical	1.2yrs	데이터 없음	데이터 없음
Bernhard Spiess	Company Secretary	no data	US$1.69m	데이터 없음

3.9yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: CSTL 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Derek Maetzold	Founder	16.8yrs	US$1.61m	1.43% $ 8.6m
Daniel Bradbury	Independent Chairman of the Board	11.8yrs	US$305.95k	0.12% $ 723.9k
G. Cole	Independent Director	5.6yrs	US$289.20k	0.048% $ 289.3k
Tiffany Olson	Independent Director	3.2yrs	US$279.20k	0.059% $ 357.1k
Kenneth Aldape	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Howard Colman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kimberlee Caple	Independent Director	3yrs	US$276.70k	0.048% $ 290.4k
Miles Harrison	Independent Director	4.3yrs	US$285.45k	0.048% $ 289.3k
Ellen Goldberg	Independent Director	3yrs	US$274.20k	0.066% $ 394.9k
Rodney Cotton	Independent Director	less than a year	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: CSTL 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.

Castle Biosciences 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Founder notifies of intention to sell stock

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Board Changes

Founder notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

Recent updates

Castle Biosciences, Inc. Announces that AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher Test

Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology

Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival (MFS) in Patients Diagnosed with UM

Consensus estimates of losses per share improve by 28%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Founder notifies of intention to sell stock

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75

Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting

Consensus EPS estimates fall by 16%, revenue upgraded

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE

Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022

Founder exercised options and sold US$141k worth of stock

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022